Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG
Authors:
- Anna C NavisANAnna C Navis
- Simone P NiclouSNSimone P Niclou
- Fred FackFFFred Fack
- Daniel StieberDSDaniel Stieber
- Sanne van LithSanne van Lith
- Kiek VerrijpKVKiek Verrijp
- Alan WrightAWAlan Wright
- Jonathan StauberJSJonathan Stauber
- Bastiaan TopsBTBastiaan Tops
- Irene Otte-HollerIOIrene Otte-Holler
- Ron A WeversRWRon A Wevers
- Arno van RooijARArno van Rooij
Open Access
- 29 May 2013
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 1 (1) , 1-12
Abstract
Background: Point mutations in genes encoding NADP+-dependent isocitrate dehydrogenases (especially IDH1) are common in lower grade diffuse gliomas and secondary glioblastomas and occur early during tumor development. The contribution of these mutations to gliomagenesis is not completely understood and research is hampered by the lack of relevant tumor models. We previously described the development of the patient-derived high-grade oligodendroglioma xenograft model E478 that carries the commonly occurring IDH1-R132H mutation. We here report on the analyses of E478 xenografts at the genetic, histologic and metabolic level. Results: LC-MS and in situ mass spectrometric imaging by LESA-nano ESI-FTICR revealed high levels of the proposed oncometabolite D-2-hydroxyglutarate (D-2HG), the product of enzymatic conversion of α-ketoglutarate (α-KG) by IDH1-R132H, in the tumor but not in surrounding brain parenchyma. α-KG levels and total NADP+-dependent IDH activity were similar in IDH1-mutant and -wildtype xenografts, demonstrating that IDH1-mutated cancer cells maintain α-KG levels. Interestingly, IDH1-mutant tumor cells in vivo present with high densities of mitochondria and increased levels of mitochondrial activity as compared to IDH1-wildtype xenografts. It is not yet clear whether this altered mitochondrial activity is a driver or a consequence of tumorigenesis. Conclusions: The oligodendroglioma model presented here is a valuable model for further functional elucidation of the effects of IDH1 mutations on tumor metabolism and may aid in the rational development of novel therapeutic strategies for the large subgroup of gliomas carrying IDH1 mutations.Keywords
This publication has 57 references indexed in Scilit:
- Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of GlioblastomaCancer Cell, 2012
- Cancer-associated Isocitrate Dehydrogenase Mutations Inactivate NADPH-dependent Reductive CarboxylationJournal of Biological Chemistry, 2012
- A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of αHGBiochemistry, 2011
- Differential Activity of NADPH-Producing Dehydrogenases Renders Rodents Unsuitable Models to Study IDH1R132 Mutation Effects in Human GlioblastomaJournal of Histochemistry & Cytochemistry, 2011
- Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolomeProceedings of the National Academy of Sciences, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1Cancer Research, 2010
- Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1αScience, 2009
- IDH1 Mutations Are Early Events in the Development of Astrocytomas and OligodendrogliomasThe American Journal of Pathology, 2009
- Genetic Pathways to Primary and Secondary GlioblastomaThe American Journal of Pathology, 2007